DGKA and neoplasm: Interestingly, this study showed that ritanserin, a DGKα-targeted inhibitor, may participate in the phospholipase D (PLD) signaling pathway, also negatively regulating the Jak-Stat and MAPK signaling pathways and exerting anti-AML tumor activity.